- Home
- TARS vs IMCR Comparison
TARS vs IMCR Comparison
Compare TARS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- IMCR
- Stock Information
- Founded
- TARS 2016
- IMCR 2008
- Country
- TARS United States
- IMCR United Kingdom
- Employees
- TARS N/A
- IMCR N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TARS Health Care
- IMCR Health Care
- Exchange
- TARS Nasdaq
- IMCR Nasdaq
- Market Cap
- TARS N/A
- IMCR 1.4B
- IPO Year
- TARS 2020
- IMCR 2021
- Fundamental
- Price
- TARS $51.28
- IMCR $29.55
- Analyst Decision
- TARS Strong Buy
- IMCR Buy
- Analyst Count
- TARS 6
- IMCR 12
- Target Price
- TARS $63.67
- IMCR $63.00
- AVG Volume (30 Days)
- TARS 628.7K
- IMCR 367.1K
- Earning Date
- TARS 05-07-2025
- IMCR 05-07-2025
- Dividend Yield
- TARS N/A
- IMCR N/A
- EPS Growth
- TARS N/A
- IMCR N/A
- EPS
- TARS N/A
- IMCR N/A
- Revenue
- TARS $182,953,000.00
- IMCR $310,202,000.00
- Revenue This Year
- TARS $90.93
- IMCR $18.97
- Revenue Next Year
- TARS $46.04
- IMCR $8.43
- P/E Ratio
- TARS N/A
- IMCR N/A
- Revenue Growth
- TARS 948.62
- IMCR 24.36
- 52 Week Low
- TARS $20.08
- IMCR $27.19
- 52 Week High
- TARS $57.28
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- TARS 57.08
- IMCR 52.19
- Support Level
- TARS $48.27
- IMCR $28.92
- Resistance Level
- TARS $52.63
- IMCR $30.04
- Average True Range (ATR)
- TARS 2.55
- IMCR 1.44
- MACD
- TARS 0.58
- IMCR 0.12
- Stochastic Oscillator
- TARS 79.89
- IMCR 62.58
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.